Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion
Sickle cell disease is an inherited disorder of hemoglobin (Hb) synthesis, caused by a single
nucleotide substitution (GTG> GAG) at the sixth codon of the β-globin gene, leading to the …
nucleotide substitution (GTG> GAG) at the sixth codon of the β-globin gene, leading to the …
No-reflow: again prevention is better than treatment
G Niccoli, RK Kharbanda, F Crea… - European heart …, 2010 - academic.oup.com
Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for
treating acute ST-segment elevation myocardial infarction (STEMI). The main goals are to …
treating acute ST-segment elevation myocardial infarction (STEMI). The main goals are to …
Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial …
I Eitel, J Wöhrle, H Suenkel, J Meissner… - Journal of the American …, 2013 - jacc.org
Objectives: The aim of the AIDA STEMI (Abciximab iv Versus ic in ST-elevation Myocardial
Infarction) cardiac magnetic resonance (CMR) substudy was to investigate potential benefits …
Infarction) cardiac magnetic resonance (CMR) substudy was to investigate potential benefits …
Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary …
YL Gu, MA Kampinga, WG Wieringa, ML Fokkema… - Circulation, 2010 - Am Heart Assoc
Background—Administration of the glycoprotein IIb/IIIa inhibitor abciximab is an effective
adjunctive treatment strategy during primary percutaneous coronary intervention for ST …
adjunctive treatment strategy during primary percutaneous coronary intervention for ST …
Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction
ML Fokkema, PJ Vlaar, T Svilaas… - European heart …, 2009 - academic.oup.com
Aims We investigated the incidence and sequelae of angiographically visible distal
embolization (AVDE) after primary percutaneous coronary intervention (PCI) in ST-elevation …
embolization (AVDE) after primary percutaneous coronary intervention (PCI) in ST-elevation …
Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome
TG Wu, Q Zhao, WG Huang, JR Wei, SW Chen… - Circulation …, 2008 - jstage.jst.go.jp
Background To investigate the efficacy of intracoronary tirofiban during primary
percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS) …
percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS) …
Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial …
S Desch, A Siegemund, U Scholz, N Adam… - Clinical Research in …, 2012 - Springer
Background In patients with ST-elevation myocardial infarction (STEMI), direct intracoronary
bolus administration of the glycoprotein (GP) IIb/IIIa receptor antagonist abciximab is …
bolus administration of the glycoprotein (GP) IIb/IIIa receptor antagonist abciximab is …
Update in pharmacological management of coronary no-reflow phenomenon
P Salinas, S Jimenez-Valero, R Moreno… - … Agents in Medicinal …, 2012 - ingentaconnect.com
The no-reflow phenomenon (NRP) is defined as the lack of adequate myocardial tissue
perfusion despite a patent epicardial coronary artery. The incidence of NRP varies between …
perfusion despite a patent epicardial coronary artery. The incidence of NRP varies between …
Rationale and design of the INFUSE-AMI study: A 2× 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration …
BACKGROUND: Whether thrombus aspiration and local glycoprotein IIb/IIIa administration
reduce infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing …
reduce infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing …
Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction …
YJ Shimada, NC Nakra, JT Fox, Y Kanei - The American journal of …, 2012 - Elsevier
Abciximab is a glycoprotein IIb/IIIa receptor inhibitor that has been shown to improve
outcomes in patients with ST-segment elevation myocardial infarction who undergo primary …
outcomes in patients with ST-segment elevation myocardial infarction who undergo primary …